Lancet: TAX 324 update

In the Lancet this week:

An update of TAX 324 is published confirming long term benefit for PFS and OS for TPF vs PF induction chemotherapy for locally advanced head and neck cancer. Clearly I think this confirms that this is the best induction regimen, however, wether induction chemotherapy is truly the best strategy remains uncertain (versus optimal up front concurrent chemo-radiotherapy), and further randomized work will be needed to establish this as the standard of care.

link

[Articles] Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial: "Induction chemotherapy with TPF provides long-term survival benefit compared with PF in locally advanced head and neck cancer. Patients who are candidates for induction chemotherapy should be treated with TPF."